Eyepoint Pharmaceuticals (NASDAQ:EYPT) Issues Earnings Results, Misses Estimates By $0.20 EPS

07 May 2026, 17:50 by Scott Moore · The Cerbat Gem

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.20), FiscalAI reports. The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%.

Here are the key takeaways from Eyepoint Pharmaceuticals’ conference call:

Phase III wet AMD readouts (LUGANO mid-year, LUCIA shortly after) are expected soon and management says two consecutive positive IDMC reviews support DURAVYU’s safety profile, which could be a near-term catalyst if top-line results are favorable.
Phase III DME programs (COMO and CAPRI) are enrolling rapidly, with management targeting full enrollment in both pivotal trials in Q3 2026 and top-line data in H2 2027, driven by strong investigator and patient interest.
Commercial and CMC readiness progressed—Northbridge cGMP facility is online, pre-approval inspection preparations underway, and the company added a Chief Commercial Officer as it builds launch capabilities for DURAVYU.
Financials show pressure—Q1 revenue fell to $0.7M (from $24.5M a year earlier) due to prior deferred revenue recognition, operating expenses rose to $88M, and net loss was $85M; cash is $223M (down from $306M) though management expects runway into Q4 2027.

Eyepoint Pharmaceuticals Stock Up 0.4%

Shares of Eyepoint Pharmaceuticals stock traded up $0.06 on Thursday, hitting $13.41. 1,121,265 shares of the company were exchanged, compared to its average volume of 1,220,794. The company has a 50-day moving average price of $14.40 and a 200 day moving average price of $14.60. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -4.24 and a beta of 1.76. Eyepoint Pharmaceuticals has a 1-year low of $5.30 and a 1-year high of $19.11.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Royal Bank Of Canada reduced their price target on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday. Citigroup increased their target price on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. HC Wainwright increased their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Chardan Capital boosted their price objective on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Eyepoint Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $31.80.

Get Our Latest Stock Report on Eyepoint Pharmaceuticals

Insiders Place Their Bets

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its position in Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Rhumbline Advisers now owns 96,280 shares of the company’s stock valued at $906,000 after purchasing an additional 9,548 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Eyepoint Pharmaceuticals by 57.8% during the second quarter. American Century Companies Inc. now owns 67,612 shares of the company’s stock worth $636,000 after buying an additional 24,752 shares during the period. Invesco Ltd. grew its holdings in shares of Eyepoint Pharmaceuticals by 199.8% during the second quarter. Invesco Ltd. now owns 128,772 shares of the company’s stock worth $1,212,000 after buying an additional 85,824 shares during the last quarter. Raymond James Financial Inc. increased its position in Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after acquiring an additional 1,177 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its stake in Eyepoint Pharmaceuticals by 9.7% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock valued at $63,988,000 after acquiring an additional 600,000 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

(Get Free Report)

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.